CXorf1 Activators
CXorf1 activators work through various mechanisms to enhance the protein's activity by influencing the biochemical cascades leading to its activation. For instance, certain activators directly stimulate adenylate cyclase, leading to an increase in intracellular cAMP levels, a secondary messenger pivotal in activating protein kinase A (PKA). Through phosphorylation, PKA can enhance the activity of CXorf1. Other activators operate by inhibiting the degradation of cAMP, thereby ensuring sustained activation of PKA and subsequent effects on CXorf1. The hormone epinephrine exemplifies a natural compound that engages adrenergic receptors, instigating a signaling cascade that culminates in elevated cAMP levels and PKA activation. Similarly, synthetic agonists mimic endogenous hormones, binding to specific receptors and triggering an increase in cAMP, which, through PKA, may promote CXorf1 phosphorylation and activation.
Moreover, additional activators can influence CXorf1 activity by modulating different aspects of the cAMP signaling pathway. PGE2, for example, binds to its receptors elevating cAMP production and thus, potentially fostering PKA-mediated phosphorylation of CXorf1. Certain toxins irreversibly activate components of the signaling cascade, leading to continuous activation of adenylate cyclase and an unrelenting rise in cAMP. This persistent signaling not only activates PKA but could also lead to a sustained increase in CXorf1 activity. Meanwhile, cAMP analogs offer a more direct route, activating PKA without requiring upstream receptor engagement, which could result in the activation of CXorf1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
This non-specific phosphodiesterase inhibitor prevents cAMP degradation, leading to enhanced PKA activity and potentially greater phosphorylation and activation of CXorf1. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
As a hormone and neurotransmitter, epinephrine binds to adrenergic receptors, causing a cascade that increases cAMP levels in cells, subsequently activating PKA and potentially increasing CXorf1 activity through phosphorylation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
This synthetic catecholamine agonist binds to and activates beta-adrenergic receptors, elevating intracellular cAMP and activating PKA. PKA could then phosphorylate and activate CXorf1. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
By specifically inhibiting PDE4, rolipram elevates intracellular cAMP, leading to PKA activation which could increase CXorf1 activity through phosphorylation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 can bind to its receptors, leading to increased cAMP production. This rise in cAMP could enhance PKA activity, which may phosphorylate and activate CXorf1. | ||||||
Glucagon trifluoroacetic acid salt | 9007-92-5 (free base) | sc-495801 | 1 mg | $480.00 | ||
This peptide hormone binds to its receptor and activates adenylate cyclase, increasing cAMP and thereby activating PKA, which can phosphorylate and activate CXorf1. | ||||||
Histamine, free base | 51-45-6 | sc-204000 sc-204000A sc-204000B | 1 g 5 g 25 g | $94.00 $283.00 $988.00 | 7 | |
Through its action on H2 receptors, histamine can increase cAMP levels, which could lead to the activation of PKA and subsequent phosphorylation and activation of CXorf1. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
As a cAMP analog, it can directly activate PKA, bypassing the need for receptor engagement, which could lead to the activation of CXorf1 through phosphorylation. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
By inhibiting PDE5, zaprinast raises cAMP and cGMP levels, which can lead to increased PKA activity and might result in the phosphorylation and activation of CXorf1. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Originally developed to inhibit platelet aggregation, anagrelide also inhibits PDE3, leading to increased cAMP levels and enhanced PKA activity, which can phosphorylate and activate CXorf1. | ||||||